ArticleFrontiers in immunology2026
Hoxb4 upregulation by Xuan Bi Tong Yu Fang confers cardioprotection via repression of the Wnt/β-catenin pathway in myocardial ischemia-reperfusion injury.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Single Genes to Systemic Networks: Transcriptomic Insights into Traditional Chinese Medicine for Heart Failure.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial ischemia-reperfusion injury (MIRI) remains a significant challenge in treating cardiovascular diseases, contributing to substantial myocardial damage and a poor prognosis. Traditional Chinese medicine (TCM) offers promising alternatives, with Xuan Bi Tong Yu Fang (XBTYF) being a classical formula known for its protective effects. However, the therapeutic mechanisms of XBTYF in MIRI have not been fully explored. Materials and methods: MIRI was induced in 36 Wistar rats, which were randomly assigned to sham, model, XBTYF (high, medium, low dose), and positive control (Qishen Yiqi Droplet) groups (n = 6). Serum levels of CK, AST, and cTnI were measured, and myocardial injury was examined by TTC, HE, and Masson staining. Bulk RNA-seq was performed to analyze gene expression profiles. The chemical composition of XBTYF was characterized by UPLC-MS/MS, followed by molecular docking to assess interactions between key compounds and Hoxb4. Results: XBTYF treatment significantly reduced myocardial enzyme levels and myocardial infarction area in the MIRI rats. Histological analysis showed improved myocardial tissue structure and reduced fibrosis. Bulk RNA-seq analysis identified Hoxb4 as a key gene restored by XBTYF and revealed a significant suppressive effect of XBTYF on the Wnt/β-catenin signaling pathway. Chemical analysis identified multiple bioactive compounds in XBTYF, and molecular docking further revealed that ginsenoside Rg3, a primary component, exhibited a strong binding affinity with the Hoxb4 protein. Conclusion: XBTYF alleviates MIRI by upregulating Hoxb4 and subsequent inhibition of the Wnt/β-catenin signaling pathway, leading to reduced cardiomyocyte apoptosis and providing cardio protection. Its effects may be linked to direct interactions between bioactive constituents, such as ginsenoside Rg3, and Hoxb4. Collectively, these findings provide mechanistic and experimental evidence supporting XBTYF as a potential adjunctive therapeutic strategy for ischemia-reperfusion-related myocardial injury and establish a molecular basis for its further translational investigation and clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.